
Divis Laboratories vs Glenmark Pharmaceuticals
Side-by-side stock comparison based on AI earnings call analysis
Which stock has stronger management signals?
Both companies need to be compared on revenue growth quality, margin trajectory and management commentary.
Divis Laboratories and Glenmark Pharmaceuticals show active capex signals based on earnings call analysis.
Glenmark Pharmaceuticals show fundraising activity or capital structure signals.
| Metric | Divis Laboratories | Glenmark Pharmaceuticals |
|---|---|---|
| Current Price | ₹11,180.5 | ₹2,648 |
| Market Cap | ₹2.97 L Cr. | ₹74,733.1 Cr. |
| Industry | Pharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology |
| P/E Ratio | 86.86 | 36.89 |
| ROE (%) | 16.53 | 23.56 |
| Debt/Equity | — | 0.13 |
| Sales Growth 5Y (%) | 8.67 | 9.19 |
| Profit Growth 5Y (%) | 65.54 | 10.97 |
| Promoter Holding (%) | 51.87 | 46.65 |
| Revenue Rank | Rank 3 | Rank 3 |
| Margin Rank | Rank 3 | Rank 2 |
| Signal | — | — |
| Capex | Yes | Yes |
| Fundraise | No information | Yes |
Analyze Divis Laboratories →Analyze Glenmark Pharmaceuticals →Divis Laboratories shareholding pattern →Glenmark Pharmaceuticals shareholding pattern →Divis Laboratories dividends →Glenmark Pharmaceuticals dividends →Compare other stocks →Stock Screener →
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.